DISCO Pharmaceuticals
DISCO Pharmaceutical's pioneering surfaceome mapping platform identifies proteins and protein communities across the entire cancer cell surface in a scalable way, boosting the discovery of meaningful targets for both mono- and bi-specific antibodies. These insights enable the development of countless cancer-selective therapies, with the potential to increase efficacy and reduce side effects for patients. DISCO is creating an internal pipeline of novel anti-cancer therapeutics leveraging this knowledge.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
discopharma.de
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.